NEW INSIGHTS INTO THE THIAZOLIDINEDIONES AS AN ADD-ON THERAPY TO METFORMIN AND GLIMEPIRIDE IN PATIENTS WITH UNCONTROLLED TYPE 2 DIABETES MELLITUS

MA ABBAS; H ULLAH; M ARBAB; AS LAGHARI; UU HAQ; Q ABBAS; B AHMED

doi:10.54112/bcsrj.v2024i1.1089

Authors

MA ABBAS Department of Public health, Health services academy Islamabad, Pakistan
H ULLAH Department of Pharmacy, Faculty of Biological, Pharmaceutical and Health Science, University of Baluchistan, Quetta, Pakistan
M ARBAB Department of Public health, Health services academy Islamabad, Pakistan
AS LAGHARI Department of Public health, Health services academy Islamabad, Pakistan
UU HAQ Department of Public health, Health services academy Islamabad, Pakistan
Q ABBAS Department of Pharmacy, Faculty of Biological, Pharmaceutical and Health Science, University of Baluchistan, Quetta, Pakistan
B AHMED Drug control and traditional Medicines division NiH Islamabad, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.1089

Keywords:

Empagliflozin, metformin, glimepiride, diabetes mellitus, HbA1c

Abstract

Diabetes mellitus is a complex metabolic disorder that requires multifaceted management, including frequent blood glucose monitoring, polypharmacy, and timely therapeutic adjustments. Thiazolidinediones have been proposed as an effective add-on therapy to existing regimens to improve glycemic control in patients with Type 2 Diabetes Mellitus (T2DM). Objective: To evaluate the effectiveness of Thiazolidinediones as add-on therapy in diabetic patients already taking metformin and glimepiride.

Methods: This observational, comparative, and follow-up cohort study was conducted in a tertiary care hospital in Pakistan. A total of 90 patients with poorly controlled T2DM were enrolled and randomly divided into two groups: Group A (n=45) received standard oral therapy with metformin and glimepiride, while Group B (n=45) received metformin, glimepiride, and Thiazolidinediones. The study outcomes included changes in Hemoglobin A1c (HbA1c), fasting blood sugar (FBS), and body mass index (BMI) throughout the study. Statistical analyses were performed using appropriate methods, with significance at p < 0.05. Results: The addition of Thiazolidinediones in Group B resulted in superior glycemic control compared to Group A. Group B exhibited a 16.1% reduction in HbA1c versus an 8.2% reduction in Group A (p < 0.05). FBS levels decreased by 28.8% in Group B compared to a 14.6% decrease in Group A (p < 0.05). Additionally, BMI decreased by 1.5% in Group B, whereas Group A showed a slight increase of 0.06% (p < 0.05). Significantly, the addition of Thiazolidinediones did not exacerbate the toxicity of the existing drug regimen. Conclusion: The study demonstrates that Thiazolidinediones, when added to standard therapy with metformin and glimepiride, offer significant improvements in glycemic control without additional toxicity. This combination therapy may be a beneficial strategy for managing poorly controlled Type 2 diabetes mellitus in the Pakistani population.

Downloads

Download data is not yet available.

References

Jawed B, Ahmed S, Abbas SQ, Ahmed Z, Andleeb S, Ahmad SA, et al. Assessment of empagliflozin add-on therapy to metformin and glimepiride in patients with inadequately controlled type-2 diabetes mellitus. Pakistan Journal of Pharmaceutical Sciences. 2022;35.

Aamir AH, Ul-Haq Z, Mahar SA, Qureshi FM, Ahmad I, Jawa A, et al. Diabetes Prevalence Survey of Pakistan (DPS-PAK): prevalence of type 2 diabetes mellitus and prediabetes using HbA1c: a population-based survey from Pakistan. BMJ open. 2019;9(2):e025300.

Donald M, Dower J, Coll JR, Baker P, Mukandi B, Doi SA. Mental health issues decrease diabetes-specific quality of life independent of glycaemic control and complications: findings from Australia’s living with diabetes cohort study. Health and quality of life outcomes. 2013;11:1-8.

Daubenmier J, Lin J, Blackburn E, Hecht FM, Kristeller J, Maninger N, et al. Changes in stress, eating, and metabolic factors are related to changes in telomerase activity in a randomized mindfulness intervention pilot study. Psychoneuroendocrinology. 2012;37(7):917-28.

Chu C-H, Hsu C-C, Lin S-Y, Chuang L-M, Liu J-S, Tu S-T. Trends in antidiabetic medical treatment from 2005 to 2014 in Taiwan. Journal of the Formosan Medical Association. 2019;118:S74-S82.

Dziadkowiec K, Stawinski P, Proenza J. S1615 Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors. Official journal of the American College of Gastroenterology| ACG. 2021;116:S726-S7.

Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care. 2018;41(12):2669.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm–2019 executive summary. Endocrine Practice. 2019;25(1):69-101.

Shin Y, Moon JH, Chin HJ, Ferrannini E, Lim S. Glycemic efficacy and metabolic consequences of an empagliflozin add-on versus conventional dose-increasing strategy in patients with type 2 diabetes inadequately controlled by metformin and sulfonylurea. Endocrinology and Metabolism. 2020;35(2):329-38.

Raosoft I. Sample size calculator by Raosoft, Inc. 2020. 2021.

Dixon JR. The international conference on harmonization good clinical practice guideline. Quality Assurance. 1999;6(2):65-74.

Lind M, Odén A, Fahlén M, Eliasson B. The true value of HbA1c as a predictor of diabetic complications: simulations of HbA1c variables. PloS one. 2009;4(2):e4412.

Swetha N. Comparison of fasting blood glucose & post prandial blood glucose with HbA1c in assessing the glycemic control. International J of Healthcare and Biomedical Research. 2014;2(3):134-9.

Kovacs CS, Seshiah V, Merker L, Christiansen AV, Roux F, Salsali A, et al. Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus. Clinical therapeutics. 2015;37(8):1773-88. e1.

Inagaki N, Watada H, Murai M, Kagimura T, Gong Y, Patel S, et al. Linagliptin provides effective, well‐tolerated add‐on therapy to pre‐existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2013;15(9):833-43.

Terauchi Y, Utsunomiya K, Yasui A, Seki T, Cheng G, Shiki K, et al. Safety and efficacy of empagliflozin as add-on therapy to GLP-1 receptor agonist (liraglutide) in Japanese patients with type 2 diabetes mellitus: a randomised, double-blind, parallel-group phase 4 study. Diabetes Therapy. 2019;10:951-63.

Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation. 2019;139(11):1384-95.

Home P. Cardiovascular outcome trials of glucose-lowering medications: an update. Diabetologia. 2019;62(3):357-69.

Schwaiger E, Burghart L, Signorini L, Ristl R, Kopecky C, Tura A, et al. Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. American Journal of Transplantation. 2019;19(3):907-19.

Manrique-Acevedo C, Chinnakotla B, Padilla J, Martinez-Lemus LA, Gozal D. Obesity and cardiovascular disease in women. International journal of obesity. 2020;44(6):1210-26.

Kim G, Gerich J, Salsali A, Hach T, Hantel S, Woerle H, et al. Empagliflozin (EMPA) increases genital infections but not urinary tract infections (UTIs) in pooled data from four pivotal phase III trials. Diabetologie und Stoffwechsel. 2014;9(S 01):P140.

Barnett A, Cradock S, Fisher M, Hall G, Hughes E, Middleton A. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. International journal of clinical practice. 2010;64(8):1121-9.